---
title: Role of Everolimus in Highly Sensitized Patients
nct_id: NCT01911546
overall_status: COMPLETED
phase: PHASE2
sponsor: Joseph Kahwaji, MD, MPH
study_type: INTERVENTIONAL
primary_condition: Highly-sensitized Kidney Transplant Recipients
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01911546.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01911546"
ct_last_update_post_date: 2017-12-07
last_seen_at: "2026-05-12T07:01:11.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Role of Everolimus in Highly Sensitized Patients

**Official Title:** A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients

**NCT ID:** [NCT01911546](https://clinicaltrials.gov/study/NCT01911546)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Joseph Kahwaji, MD, MPH
- **Collaborators:** Novartis
- **Conditions:** Highly-sensitized Kidney Transplant Recipients
- **Start Date:** 2013-06
- **Completion Date:** 2016-01-19
- **CT.gov Last Update:** 2017-12-07

## Brief Summary

A growing number of patients on the kidney transplant waiting list are broadly human leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible donor. Therefore they wait longer and have increased morbidity and mortality. Desensitization with intravenous immune globulin (IVIG) and rituximab with alemtuzumab induction improves transplant rates and achieves good allograft outcomes. However, HS patients are at risk for viral infections after transplant. We have previously shown an increased incidence of BKV infections after desensitization with HS patients having higher peak viral loads. Cytomegalovirus (CMV) and polyomavirus BK (BKV) infections place HS renal transplant recipients at particular risk. Allograft rejection is associated with both CMV and BKV infection. This is of particular concern for HS patients as they are at an increased risk of rejection at baseline. Furthermore, the frequent development of leukopenia after transplantation often requires the CMV prophylactic agent to be discontinued along with lowering immunosuppression. This increases the risk of CMV infection and allograft rejection.

Everolimus was approved for rejection prophylaxis in combination with calcineurin inhibitors (CNI). CNI used in the study that led to drug's approval was cyclosporine. There are several trials nearing it's completion that utilize low dose tacrolimus instead. In 2012 Novartis published data from several trials showing superior outcomes using everolimus + low dose tacrolimus. This combination is currently approved in EU. It is also a combination that is standard of care (SOC) at our center for patients on everolimus.

This study aims to demonstrate that use of everolimus as part of a maintenance immunosuppression regimen may decrease viral infections without lowering overall immunosuppression thus improving allograft function and survival.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Recipient of a deceased or living donor kidney allograft
2. Patients must have undergone desensitization with IVIG and rituximab with or without plasma exchange prior to transplant or be administered IVIG and rituximab peri-operatively.
3. Age 18 and over
4. Able to understand and provide informed consent

Exclusion Criteria:

Recipients of a dual simultaneous kidney/liver, kidney/heart, kidney/lung transplant 2. Pregnant or lactating females 3. Patients with a platelet count \< 100,000/mm3 at time of randomization 4. Patients with an absolute neutrophil count \< 1,500/mm3 or a white blood cell count of \<3,000/mm3 at time of randomization 5. Patients who have an abnormal liver profile such as ALT, AST, Alkaline Phosphatase, or total bilirubin \> 3 times the upper limit of normal (ULN) at time of randomization 6. Patients with severe total hypercholesterolemia (\> 350 mg/dL; \> 9 mmol/L) or total hypertriglyceridemia (\> 500 mg/dL; \> 5.6 mmol/L). Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable.

7\. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes 8. Patients being treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4 9. Patients with a clinically significant systemic infection within 30 days prior to transplant 9 10. Patients who have any surgical or medical condition, such as severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism and/or excretion of study medication.

11\. Patients with a history of coagulopathy or medical condition that would require long-term anticoagulation therapy after transplantation, unless the condition would permit a two week interruption in therapy before and after allograft biopsy. (Treatment with low dose aspirin is allowed.) 12. Women of childbearing potential who are either pregnant, lactating, planning to become pregnant during this trial, or with a positive serum or urine pregnancy test. Women of childbearing potential must be willing to agree to contraceptive practices.
```

## Arms

- **everolimus + low-dose tacrolimus** (EXPERIMENTAL) — Patients receiving everolimus will be on low dose tacrolimus.

## Interventions

- **everolimus + low-dose tacrolimus** (DRUG) — Patients are supplied everolimus (Zortress) + prograf

## Primary Outcomes

- **The Number of Polyoma BK Viremia Patients** _(time frame: 12 months)_ — Patients will be monitored at regular interval for the development of Polyomavirus Viremia.
- **The Number of CMV Viremia** _(time frame: 12 Months)_ — The number of patients with CMV viremia
- **Incidence of Antibody Mediated Rejection (ABMR)** _(time frame: 6 months)_ — Protocol biopsies were obtained at T0 and 6 months post transplant.

## Secondary Outcomes

- **Incidence of Cell Mediated Rejection (CMR)** _(time frame: 6 months)_

## Locations (1)

- Cedars-Sinai Medical Center, Los Angeles, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cedars-sinai medical center|los angeles|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01911546.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01911546*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*